➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Johnson and Johnson
AstraZeneca
Dow

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Dinaciclib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Dinaciclib?

Dinaciclib is an investigational drug.

There have been 13 clinical trials for Dinaciclib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Merck Sharp & Dohme Corp., and AbbVie.

There are ten US patents protecting this investigational drug and one hundred and fifty-three international patents.

Recent Clinical Trials for Dinaciclib
TitleSponsorPhase
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaMerck Sharp & Dohme Corp.Phase 1
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAbbViePhase 1
Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerMerck Sharp & Dohme Corp.Phase 1/Phase 2

See all Dinaciclib clinical trials

Clinical Trial Summary for Dinaciclib

Top disease conditions for Dinaciclib
Top clinical trial sponsors for Dinaciclib

See all Dinaciclib clinical trials

US Patents for Dinaciclib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dinaciclib   Start Trial Pharmaceutical combination for the treatment of cancer PIRAMAL ENTERPRISES LIMITED (Mumbai, IN)   Start Trial
Dinaciclib   Start Trial Pyrazolopyrimidines as cyclin dependent kinase inhibitors Schering Corporation (Kenilworth, NJ) Pharmacopeia Drug Discovery, Inc. (Cranbury, NJ)   Start Trial
Dinaciclib   Start Trial Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors Schering Corpoartion (Kenilworth, NJ)   Start Trial
Dinaciclib   Start Trial Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same Schering Corporation (Kenilworth, NJ)   Start Trial
Dinaciclib   Start Trial Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-ami- no derivatives and intermediates Schering Corporation (Kenilworth, NJ)   Start Trial
Dinaciclib   Start Trial Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dinaciclib

Drugname Country Document Number Estimated Expiration Related US Patent
Dinaciclib European Patent Office EP3148532 2034-05-28   Start Trial
Dinaciclib World Intellectual Property Organization (WIPO) WO2015181737 2034-05-28   Start Trial
Dinaciclib Argentina AR041137 2022-09-04   Start Trial
Dinaciclib Argentina AR047543 2022-09-04   Start Trial
Dinaciclib Argentina AR056873 2022-09-04   Start Trial
Dinaciclib Argentina AR063096 2022-09-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Johnson and Johnson
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.